I farmaci antitrombotici nella donna: Dobbiamo avere più paura delle emorragie?

Translated title of the contribution: Antithrombotic drugs in women: Should we worry more about bleeding?

Rosanna Abbate, Gabriele Cioni, Rossella Marcucci, Cinzia Fatini, Gian Franco Gensini

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Since the mid '90s, the concept of evidence-based medicine has grown exponentially, contributing to the advancement of personalized medicine, which considers the "female gender" as an extremely important area of customization, but orphan of targeted research. Strong evidence do exists demonstrating gender differences in bleeding risk associated with antithrombotic treatment, mostly related to lower values of body mass, organ size and renal function in women than men. Across clinical studies, the search for the specific risk of bleeding in the female vs male gender has gained attention only recently; therefore, data from different studies and relatively limited meta-analyses should be assessed carefully. As for antiplatelet therapy for primary prevention, the risk of major bleeding events, such as cerebral hemorrhage, is lower for women than for men. Conversely, in acute situations in which antithrombotic drugs are given in association, the risk of bleeding is greater for women, in particular for combination therapies with heparin or low molecular weight heparin or thrombolytic agents. Numerous studies in the literature evaluated the incidence of minor and major bleeding during oral anticoagulant therapy in relation to gender, but the results are not entirely consistent and appear to vary over the years. In summary, there are some aspects of guidance in the complex spectrum of the bleeding risk related to antithrombotic treatment, with indications of a lower bleeding risk in women than men related to long-term preventive single antithrombotic drug treatments. In addition, hormonal effects and use of outprescribed drugs may also play a significant role in modulating hemostasis.

Original languageItalian
Pages (from-to)407-413
Number of pages7
JournalGiornale Italiano di Cardiologia
Volume13
Issue number6
DOIs
Publication statusPublished - Jun 2012

Fingerprint

Hemorrhage
Pharmaceutical Preparations
Therapeutics
Precision Medicine
Orphaned Children
Fibrinolytic Agents
Organ Size
Evidence-Based Medicine
Low Molecular Weight Heparin
Cerebral Hemorrhage
Primary Prevention
Interpersonal Relations
Hemostasis
Anticoagulants
Heparin
Meta-Analysis
Kidney
Incidence
Research

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

I farmaci antitrombotici nella donna : Dobbiamo avere più paura delle emorragie? / Abbate, Rosanna; Cioni, Gabriele; Marcucci, Rossella; Fatini, Cinzia; Gensini, Gian Franco.

In: Giornale Italiano di Cardiologia, Vol. 13, No. 6, 06.2012, p. 407-413.

Research output: Contribution to journalArticle

Abbate, R, Cioni, G, Marcucci, R, Fatini, C & Gensini, GF 2012, 'I farmaci antitrombotici nella donna: Dobbiamo avere più paura delle emorragie?', Giornale Italiano di Cardiologia, vol. 13, no. 6, pp. 407-413. https://doi.org/10.1714/1073.11758
Abbate, Rosanna ; Cioni, Gabriele ; Marcucci, Rossella ; Fatini, Cinzia ; Gensini, Gian Franco. / I farmaci antitrombotici nella donna : Dobbiamo avere più paura delle emorragie?. In: Giornale Italiano di Cardiologia. 2012 ; Vol. 13, No. 6. pp. 407-413.
@article{9d905880cf2f465bb63719a5f759a8d6,
title = "I farmaci antitrombotici nella donna: Dobbiamo avere pi{\`u} paura delle emorragie?",
abstract = "Since the mid '90s, the concept of evidence-based medicine has grown exponentially, contributing to the advancement of personalized medicine, which considers the {"}female gender{"} as an extremely important area of customization, but orphan of targeted research. Strong evidence do exists demonstrating gender differences in bleeding risk associated with antithrombotic treatment, mostly related to lower values of body mass, organ size and renal function in women than men. Across clinical studies, the search for the specific risk of bleeding in the female vs male gender has gained attention only recently; therefore, data from different studies and relatively limited meta-analyses should be assessed carefully. As for antiplatelet therapy for primary prevention, the risk of major bleeding events, such as cerebral hemorrhage, is lower for women than for men. Conversely, in acute situations in which antithrombotic drugs are given in association, the risk of bleeding is greater for women, in particular for combination therapies with heparin or low molecular weight heparin or thrombolytic agents. Numerous studies in the literature evaluated the incidence of minor and major bleeding during oral anticoagulant therapy in relation to gender, but the results are not entirely consistent and appear to vary over the years. In summary, there are some aspects of guidance in the complex spectrum of the bleeding risk related to antithrombotic treatment, with indications of a lower bleeding risk in women than men related to long-term preventive single antithrombotic drug treatments. In addition, hormonal effects and use of outprescribed drugs may also play a significant role in modulating hemostasis.",
keywords = "Antithrombotic drugs, Bleeding, Cardiovascular prevention, Female gender, Oral anticoagulant therapy",
author = "Rosanna Abbate and Gabriele Cioni and Rossella Marcucci and Cinzia Fatini and Gensini, {Gian Franco}",
year = "2012",
month = "6",
doi = "10.1714/1073.11758",
language = "Italian",
volume = "13",
pages = "407--413",
journal = "Giornale Italiano di Cardiologia",
issn = "1827-6806",
publisher = "CEPI s.r.l.",
number = "6",

}

TY - JOUR

T1 - I farmaci antitrombotici nella donna

T2 - Dobbiamo avere più paura delle emorragie?

AU - Abbate, Rosanna

AU - Cioni, Gabriele

AU - Marcucci, Rossella

AU - Fatini, Cinzia

AU - Gensini, Gian Franco

PY - 2012/6

Y1 - 2012/6

N2 - Since the mid '90s, the concept of evidence-based medicine has grown exponentially, contributing to the advancement of personalized medicine, which considers the "female gender" as an extremely important area of customization, but orphan of targeted research. Strong evidence do exists demonstrating gender differences in bleeding risk associated with antithrombotic treatment, mostly related to lower values of body mass, organ size and renal function in women than men. Across clinical studies, the search for the specific risk of bleeding in the female vs male gender has gained attention only recently; therefore, data from different studies and relatively limited meta-analyses should be assessed carefully. As for antiplatelet therapy for primary prevention, the risk of major bleeding events, such as cerebral hemorrhage, is lower for women than for men. Conversely, in acute situations in which antithrombotic drugs are given in association, the risk of bleeding is greater for women, in particular for combination therapies with heparin or low molecular weight heparin or thrombolytic agents. Numerous studies in the literature evaluated the incidence of minor and major bleeding during oral anticoagulant therapy in relation to gender, but the results are not entirely consistent and appear to vary over the years. In summary, there are some aspects of guidance in the complex spectrum of the bleeding risk related to antithrombotic treatment, with indications of a lower bleeding risk in women than men related to long-term preventive single antithrombotic drug treatments. In addition, hormonal effects and use of outprescribed drugs may also play a significant role in modulating hemostasis.

AB - Since the mid '90s, the concept of evidence-based medicine has grown exponentially, contributing to the advancement of personalized medicine, which considers the "female gender" as an extremely important area of customization, but orphan of targeted research. Strong evidence do exists demonstrating gender differences in bleeding risk associated with antithrombotic treatment, mostly related to lower values of body mass, organ size and renal function in women than men. Across clinical studies, the search for the specific risk of bleeding in the female vs male gender has gained attention only recently; therefore, data from different studies and relatively limited meta-analyses should be assessed carefully. As for antiplatelet therapy for primary prevention, the risk of major bleeding events, such as cerebral hemorrhage, is lower for women than for men. Conversely, in acute situations in which antithrombotic drugs are given in association, the risk of bleeding is greater for women, in particular for combination therapies with heparin or low molecular weight heparin or thrombolytic agents. Numerous studies in the literature evaluated the incidence of minor and major bleeding during oral anticoagulant therapy in relation to gender, but the results are not entirely consistent and appear to vary over the years. In summary, there are some aspects of guidance in the complex spectrum of the bleeding risk related to antithrombotic treatment, with indications of a lower bleeding risk in women than men related to long-term preventive single antithrombotic drug treatments. In addition, hormonal effects and use of outprescribed drugs may also play a significant role in modulating hemostasis.

KW - Antithrombotic drugs

KW - Bleeding

KW - Cardiovascular prevention

KW - Female gender

KW - Oral anticoagulant therapy

UR - http://www.scopus.com/inward/record.url?scp=84864799630&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864799630&partnerID=8YFLogxK

U2 - 10.1714/1073.11758

DO - 10.1714/1073.11758

M3 - Articolo

C2 - 22622119

AN - SCOPUS:84864799630

VL - 13

SP - 407

EP - 413

JO - Giornale Italiano di Cardiologia

JF - Giornale Italiano di Cardiologia

SN - 1827-6806

IS - 6

ER -